Biocon Group chairperson Kiran Mazumdar-Shaw predicts FY26 as a growth year, fueled by biosimilars, generics, and research ...

Kiran Mazumdar-Shaw discusses the impact of US drug price reduction efforts on Indian pharma, Biocon's US expansion, strong ...

Kiran Mazumdar-Shaw suggestion was met with a flurry of responses, with many users pushing back against the idea.

Kiran Mazumdar-Shaw urges India to unlock its trillion-dollar orange economy potential by 2047 through tech-driven ...

said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, adding that one needs to wait for more details on the order to ascertain the full impact. Speaking to CNBC TV18 on May 13 ...

Upgrad Co-Founder Ronnie Screwvala reshared a post by ex-Indian Olympian Abhinav Bindra on World Mental Health Day. Bindra wrote on X (Twitter), “In the race of life, we often chase gold and glory.

Biosimilars, too, are expected to gain ground as healthcare systems worldwide look for cost-effective alternatives to ...

The Chairperson of Biocon Group said that generics and biosimilars are clearly part of the Affordable Care Act, but they are not the target of President Trump's current efforts.

Touching on India’s demographic advantage, Shaw highlighted the country’s youth and digital infrastructure as key assets.

The company said its Board approved a fundraise of up to Rs 4,500 crore and is also evaluating a potential merger of Biocon ...

Bengaluru: Biocon, an Indian biopharmaceutical company, has reported a more than twofold increase in its fourth-quarter ...

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ...